- Investing Ideas
- U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
U.K. Pharmaceuticals & Biotech Healthy potentially undervalued
Results
5
Companies which are potentially undervalued and in an acceptable financial position.
5 companies
Diaceutics
Market Cap: UK£119.8m
A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.
DXRX
UK£1.42
7D
-1.0%
1Y
9.7%
GSK
Market Cap: UK£77.4b
Engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
GSK
UK£19.38
7D
3.0%
1Y
28.1%
Oxford Biomedica
Market Cap: UK£761.8m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£6.30
7D
0.3%
1Y
83.4%
HUTCHMED (China)
Market Cap: UK£1.4b
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
HCM
UK£1.62
7D
-7.7%
1Y
-28.2%
Hikma Pharmaceuticals
Market Cap: UK£3.1b
Develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
HIK
UK£14.71
7D
-0.3%
1Y
-30.9%